Due to this similarity across these FGFR1 fusions, PLCγ1 inhibition may be a beneficial therapeutic target in treating FGFR1 translocation induced myeloproliferative neoplasms. This evidence concerns the gene FGFR1 and myeloproliferative neoplasm.